A coalition of unions, consumer groups, and public interest organizations are urging the Federal Trade Commission to challenge a $16.5 billion deal where Novo Nordisk’s parent foundation would acquire Catalent, a leading contract drug manufacturer. The coalition is concerned that the acquisition may harm competition and reduce patient access to popular diabetes and weight loss medicines. Novo currently holds a 54% share of the North American market for GLP-1 drugs, while Catalent provides specialized development and manufacturing services for these medicines. If the deal goes through, Novo could potentially disadvantage its rivals in favor of its own products, leading to concerns raised by Eli Lilly, a chief Novo rival.
Source link
Consumer, labor groups urge FTC to block Catalent sale to Novo Holdings
